Skip to main content
Download PDF

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients

Journal for ImmunoTherapy of Cancer volume 7, Article number: 9 (2019) Cite this article

The Original Article was published on 03 October 2018

Correction to: Journal for ImmunoTherapy of Cancer (2018) 6:101

Doi 10.1186/s40425-018-0421-z

Following publication of the original article [1], the authors reported an error in their listed affiliations.

In this Correction Dr. Jiaxin Zhao is related to two affiliations:

1. The Second Affiliated Hospital & Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou, China.

3. The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.

The published apologizes for any inconvenience caused by this error.

Reference

  1. Zhao, et al. Journal for ImmunoTherapy of Cancer. 2018;6(101). https://doi.org/10.1186/s40425-018-0421-z.

Download references

Author information

Authors and Affiliations

  1. The Second Affiliated Hospital & Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou, China

    Bin Zhao

  2. The Third Affiliated Hospital of Harbin Medical University, Harbin, China

    Hong Zhao

  3. The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China

    Jiaxin Zhao

Authors
  1. Bin Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hong Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jiaxin Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Bin Zhao, Hong Zhao or Jiaxin Zhao.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, B., Zhao, H. & Zhao, J. Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients. j. immunotherapy cancer 7, 9 (2019). https://doi.org/10.1186/s40425-018-0487-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40425-018-0487-7